Phico Therapeutics

by Bacteriophage.news
Phico Therapeutics
Category

Phico Therapeutics is a biotechnology company developing a novel platform technology which it believes could form the basis for a new generation of antibiotics to fight against drug-resistant bacteria. The company’s patented platform utilizes an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. With a number of advantages over conventional antibiotic classes, SASPject™ could form the basis for a new generation of antibiotics to overcome antimicrobial resistance.

Bacteriophage product pipeline:

  • SASPject PT3.9 – target: Pseudomonas aeruginosa
  • SASPject PT4 – target: Klebsiella pneumoniae – for intravenous use
  • SASPject PT5 – target: Escherichia coli – for intravenous use
  • SASPject PT1.2 – target: Staphylococcus aureus – for intra-nasal use

This website uses cookies. Accept Read More